Literature DB >> 19458614

The clinical utility index as a practical multiattribute approach to drug development decisions.

B Poland1, F L Hodge, A Khan, R T Clemen, J A Wagner, K Dykstra, R Krishna.   

Abstract

We identify some innovative approaches to predicting overall patient benefit from investigational drugs to support development decisions. We then illustrate calculation of a probabilistic clinical utility index (CUI), an implementation of multiattribute utility that focuses on clinical attributes. We recommend use of the CUI for the support of early drug development decisions because of its practicality, reasonable accuracy, and transparency to decision makers, at stages in which financial factors that may dominate later-phase decisions are less critical.

Entities:  

Mesh:

Year:  2009        PMID: 19458614     DOI: 10.1038/clpt.2009.71

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

2.  Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.

Authors:  Rosemary Wyber; Ben J Boyd; Samantha Colquhoun; Bart J Currie; Mark Engel; Joseph Kado; Ganesan Karthikeyan; Mark Sullivan; Anita Saxena; Meru Sheel; Andrew Steer; Joseph Mucumbitsi; Liesl Zühlke; Jonathan Carapetis
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

Review 3.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

4.  Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.

Authors:  Simone Tomasi; Paolo Sarmientos; Giada Giorda; Victor Gurewich; Alessandro Vercelli
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

5.  Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.

Authors:  Rui Zhu; Bill Poland; Russ Wada; Qi Liu; Luna Musib; Daniel Maslyar; Eunpi Cho; Wei Yu; Han Ma; Jin Yan Jin; Nageshwar Budha
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-03-06

6.  COVID-19 vaccines and treatments: When speed is necessary and not enough.

Authors:  Thaddeus H Grasela; David A Price; John A Wagner
Journal:  Clin Transl Sci       Date:  2021-04-09       Impact factor: 4.438

7.  Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor.

Authors:  E Raddad; M R Melhem; J S Sloan-Lancaster; J W Miller; S A Van Wart; C M Rubino
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-08-21

8.  Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine.

Authors:  Lena Brynne; Anders Bresell; Niclas Sjögren
Journal:  J Transl Med       Date:  2013-10-08       Impact factor: 5.531

9.  A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data.

Authors:  Insa Winzenborg; Ahmed M Soliman; Mohamad Shebley
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.